2015年1月14日,

2008年2月13日0评论遗传图谱,“开发人员即时分子诊断方法的耐甲氧西林金黄色葡萄球菌和脑膜炎等指标,提出了在风险投资210万英镑。新闻稿西南投资基金和财政西南增长基金2.1英镑进一步“公司的一轮融资,阿特拉斯基因,这是发展的角度关心的分子诊断平台,给临床医生的结果在不到30分钟从病人样本。公司目前正在测试脑膜炎,衣原体,B群链球菌和医院“super-bug”耐甲氧西林金黄色葡萄球菌。公司成立于2005年作为一个从巴斯大学打滑失控,引发了额外的资金进行临床评价的B群链球菌检测孕妇,感染可导致致命的败血症和脑膜炎在新生的孩子。这最新一轮看到进一步融资提供的现有投资者,西南企业基金,GEIF和私人投资者通过情郎商业天使网络。新投资者全面金融西南增长基金和勇敢的心企业。Atlas遗传学发展的护理VeloxTM系统,便携式设备提供的好处分子一起测试实验室质量结果,在30分钟。这允许医生检测和治疗患者在一个访问中或在紧急情况下有一个特定的诊断。这相当于对病人有更好的效果。除了它允许临床医生开出最有效的药物,而不是使用广泛的抗生素可以鼓励“super-bugs”。 In the VeloxTM system a patient sample, such as blood or urine, is loaded directly into a disposable card which is then inserted into a reader instrument. An electronic tag developed by the company automatically indicates the presence of DNA from the pathogen responsible for the infection. This technology offers significant advantages over conventional methods and makes it feasible to produce a simple to use and portable device with the sensitivity and specificity of central laboratory equipment. Development of the disposable card is being undertaken with the world-leading micro-fluidic company Micronics Inc, based in Seattle. Dr John Clarkson, Chief Executive Officer of Atlas Genetics, said: “The initial funding secured from our investors has enabled us to produce the prototype disposable card, and this second round will take us through development to the point where the Group B Strep system can be evaluated with clinical samples.” Nick Simmonds, Investment Manager at YFM Group, manager of the South West Ventures Fund, said: “This second round of funding will allow Atlas Genetics to develop a platform for many exciting applications. The market for point of care molecular diagnostics is expanding rapidly and is allowing earlier treatment of potentially serious infections. We are delighted to back Atlas Genetics and look forward to working closely with the company as it develops.”